Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04727606
Other study ID # 20.259
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date January 15, 2023
Est. completion date June 15, 2024

Study information

Verified date November 2022
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In clinical practice, many patients are not able to modify their habits to achieve a high level of diuresis and fluid intake and therefore are at an elevated risk for stone recurrence. The investigators think that Ure-Na (osmotic agent) taking could help to increase urine volume and decrease urine concentration, which would be of benefit in the prevention of kidney stones.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 15, 2024
Est. primary completion date January 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - 18 to 60 years of age - High risk for recurrence (1 or more of) Bilateral or complex stones, Recurrent stones, Family history (1st degree relative), Non-calcium stones, Solitary kidney or anatomical abnormality, Nephrocalcinosis, Systemic disease with risk of stones (tubular acidosis, cystinuria, etc.) - Diuresis < 1.8 L/24 hours despite recommendations from physicians and/or nutritionist at the kidney stone clinic (as documented in the previous 6 months) Exclusion Criteria: - Patient does not meet 1 of the 3 inclusion criteria - Pregnancy or breastfeeding - Lack of understanding about the protocol and effects of Ure-Na - Expected inability to adequately increase fluid intake on Ure-Na

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ure-Na
Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day) Treatment will continue for approximately 1 month.

Locations

Country Name City State
Canada Centre Hospitalier de l'Université de Montréal (CHUM) Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)

Country where clinical trial is conducted

Canada, 

References & Publications (7)

Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol. 2008 Jun;19(6):1076-8. doi: 10.1681/ASN.2007091042. Epub 2008 Mar 12. — View Citation

Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996 Mar;155(3):839-43. — View Citation

Decaux G, Brimioulle S, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med. 1980 Jul;69(1):99-106. — View Citation

Dion M, Ankawi G, Chew B, Paterson R, Sultan N, Hoddinott P, Razvi H. CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update. Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E347-E358. doi: 10.5489/cuaj.4218. Epub 2016 Nov 10. — View Citation

Nayan M, Elkoushy MA, Andonian S. Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. Can Urol Assoc J. 2012 Feb;6(1):30-3. doi: 10.5489/cuaj.11131. — View Citation

Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol. 2012 May;7(5):742-7. doi: 10.2215/CJN.06990711. Epub 2012 Mar 8. — View Citation

Verbalis JG, Baldwin EF, Neish PN, Robinson AG. Effect of protein intake and urea on sodium excretion during inappropriate antidiuresis in rats. Metabolism. 1988 Jan;37(1):46-54. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in urine output at 1 week and 1 Month variation in 24-hour diuresis and urine biochemistry 1 week and 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT04495699 - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Recruiting NCT04559321 - Holmium Vs Trilogy Kidney Stones GUY's 1-2 Phase 3
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Not yet recruiting NCT05022537 - Clinical Outcomes of Percutaneous Nephrolithotomy Following Retrograde Percutaneous Nephrostomy Access Using Novel Device in Comparison to Antegrade Access N/A
Completed NCT03872843 - Opioid Free Management After Ureteroscopy Phase 4
Recruiting NCT06412822 - Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone
Active, not recruiting NCT06437379 - Infection Control Measures for Patients Undergoing Percutaneous Nephrolithotomy N/A
Recruiting NCT04997668 - Clinical Outcomes and Healthcare Economics of SOLTIVE Compared to Ho:YAG Laser in Urolithiasis N/A
Active, not recruiting NCT04333745 - Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers N/A
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Recruiting NCT04389853 - Mini-PNCL vs fURS in Management of Nephrolithiasis N/A
Recruiting NCT05334979 - Oxalate and Citrate N/A
Recruiting NCT05591716 - Evaluation of the Efficacy and Safety of Unimodal Bilateral Flexible Ureteroscopy. N/A
Recruiting NCT06209931 - RIRS With Tip Flexible Pressure-controlling Ureteral Access Sheath Versus Mini PCNLfor Kidney Stones
Withdrawn NCT04545528 - The Impact of Nutritional Service in the Stone Clinic on the Patient Urine Collection Results
Completed NCT05714423 - Outcomes in Lower Pole Kidney Stone Management Using Mini-PCNL Compared With Retrograde Intra Renal Surgery N/A
Recruiting NCT03281928 - Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling N/A
Recruiting NCT04835922 - Comparison of Efficacy of Intercostal Nerve Block vs Peritract Infiltration With 0.25% Bupivacaine in PCNL N/A
Recruiting NCT03257306 - Magnetic Ureteral Stent Symptoms - a Comparison to Standard Ureteral Stent as Perceived By the Patient (MAGUSS) N/A